You are here: Welcome to the MPKB » Welcome to the MPKB » Starting the Marshall Protocol » Working with your physician » Helping a concerned physician to become comfortable with the MP
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:starting:physician:reluctant [04.30.2019] – [Specific research] sallieqhome:starting:physician:reluctant [06.01.2019] – [Specific research] sallieq
Line 193: Line 193:
  
  
-Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat)(({{pubmed>long:20074257}}))  PMID 20074257+Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.[in rat](({{pubmed>long:20074257}}))  PMID 20074257
  
 Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed>long:19304450}}))   PMID 19304450 Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed>long:19304450}}))   PMID 19304450
Line 209: Line 209:
  
  
-6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats (({{pubmed>long:23775504}} )) PMID 23775504+6 mg/kg olmesartan reduces the inflammatory process and bone loss [in rats] (({{pubmed>long:23775504}} )) PMID 23775504 
 + 
 +Olmesartan at a dose of 10 mg/kg prevented the mucosal damage and inflammation associated with 5-FU-induced OM, increasing granulation and tissue repair. [in hamsters] (({{pubmed>long:    30125396}}))
  
  
home/starting/physician/reluctant.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.